Skip to main content
AAN.com
Contemporary Issues in Practice, Education, & Research
January 10, 2022

Comment: Introducing Neuromodulation in 2035
Future Forecasting Series

January 11, 2022 issue
98 (2) 64

Abstract

One of the easiest ways to conjure a futuristic image of medicine is to discuss how devices—implanted and otherwise—will be integrated into clinical care. In this issue of Neurology®, Drs. Denison and Morrell1 explore the rapidly advancing field of neuromodulation, and how it will affect the care of neurologic patients in 2035.

Get full access to this article

View all available purchase options and get full access to this article.

Reference

1.
Denison T, Morrell MJ. Neuromodulation in 2035: the Neurology Future Forecasting Series. Neurology. 2022;98(2):65-72.

Information & Authors

Information

Published In

Neurology®
Volume 98Number 2January 11, 2022
Pages: 64
PubMed: 35263272

Publication History

Published online: January 10, 2022
Published in print: January 11, 2022

Permissions

Request permissions for this article.

Disclosure

Dr. Jones serves as a voluntary board member of the AANI and the Mayo Clinic ACO. Dr. Gross reports support from the University of Rochester CTSI and book royalty income for Neurology in Practice. Go to Neurology.org/N for full disclosures.

Authors

Affiliations & Disclosures

Lyell K. Jones Jr, MD
From the Mayo Clinic (L.K.J.), Rochester, MN; and University of Rochester (R.A.G.), NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Neurology: Clinical Practice, Editorial Board, 2016 to present
Patents:
1.
NONE
Publishing Royalties:
1.
Mayo Clinic Neurology Board Review book, Oxford University Press, 2015
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
Voluntary member of the AANI Board of Directors Voluntary member of the Mayo Clinic ACO Board of Directors Voluntary chair of the American Academy of Neurology Quality Committee Teaching honoraria from the American Academy of Neurology
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Robert A. Gross, MD, PhD
From the Mayo Clinic (L.K.J.), Rochester, MN; and University of Rochester (R.A.G.), NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Received honorarium from AAN as Editor-in-Chief of Neurology (through Q1 2020).
Editorial Boards:
1.
Served as Editor-in-Chief of Neurology 2009-2020.
Patents:
1.
NONE
Publishing Royalties:
1.
Neurology in Practice (series); Blackwell-Wiley; 2011-2021
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
Has conducted clinical trials funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus, but has ceased participation in industry-sponsored clinical trials and speakers' bureau since appointment as EIC for Neurology (2009).
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) UL1 TR002001 Bennett/Zand (MPI) 07/15/2020 - 06/30/2025 NIH/National Center for Advancing Translational Sciences The University of Rochester’s Clinical and Translational Science Institute $19,107,872 2% effort on Digital Health & Regulatory Science; 5% effort on the Translational Endeavors Core (ended on 12/31/2020)
Research Support, Academic Entities:
1.
UT Austin: Grand Rounds Honorarium ($500) - 2021 Stock/Stock Options, Medical Equipment & Materials: Note: All since term as editor ended 1. Amgen, 2020- 2. GSK, 2020- 3. J&J, 2020- 4. Merck, 2020- 5. Pfizer, 2020- 6. Procter & Gamble, 2020-
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share